Both CEP and PFD significantly decreased the levels of IL-6 (5.35–8.66 ng/mL) and TGF-β1 (8372.1–9572.2 pg/mL) contents in the serum when compared to that in the BLM-treated group (Figure 3C,D). The gene discussed is IL6; the disease is polyostotic fibrous dysplasia.